Key Insights

Highlights

Success Rate

100% trial completion (above average)

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 50/100

Termination Rate

0.0%

0 terminated out of 50 trials

Success Rate

100.0%

+13.5% vs benchmark

Late-Stage Pipeline

2%

1 trials in Phase 3/4

Results Transparency

0%

0 of 6 completed with results

Key Signals

100% success

Data Visualizations

Phase Distribution

24Total
Not Applicable (22)
P 1 (1)
P 3 (1)

Trial Status

Recruiting21
Not Yet Recruiting14
Completed6
Active Not Recruiting4
Enrolling By Invitation3
Unknown2

Trial Success Rate

100.0%

Benchmark: 86.5%

Based on 6 completed trials

Clinical Trials (50)

Showing 20 of 20 trials
NCT07506889Not Yet RecruitingPrimary

Simplified Exercise-based Risk Assessment in Lung Cancer

NCT06559059RecruitingPrimary

Evaluating the Implementation of a Comprehensive Multilevel Virtual Oncology Program Among Veterans Diagnosed With Lung, Colorectal, Prostate, and Breast Cancers in the US Department of Veterans Affairs

NCT07168993Not ApplicableRecruitingPrimary

Evaluate the Clinical Performance of the Flow Cytometry - FlowPath Lung Test as a Sensitive and Specific Non-invasive Diagnostic of Sputum Samples to Identify/Detect the Presence of Lung Cancer in High-risk Individuals Who Have Existing Lung Nodules, 6 to <30 mm in Diameter, Determined by LDCT.

NCT07396467Active Not RecruitingPrimary

Clinical Outcomes and Immunotherapy in Lung Cancer With Pulmonary Fibrosis

NCT07465848Not ApplicableRecruitingPrimary

Prospective Multicentre Study for the Application of Telomere Measurement Technology as a Tool for Lung Cancer Diagnosis

NCT07439991RecruitingPrimary

Study of Risk Factors and Prediction of Blood Clots After Lung Cancer Surgery

NCT07426718Not Yet RecruitingPrimary

A Study Measuring Markers of Airway Inflammation in Breath Samples From People With Respiratory Diseases and Healthy Volunteers.

NCT07410676Phase 1Recruiting

EBNK-001 Allogeneic NK Cells With Low-Dose IL-15 ± Pembrolizumab in Advanced Solid Tumors

NCT07418450Not ApplicableRecruitingPrimary

Discrimination of N2a and N2b by EBUS-TBNA: is a Change of the Needle Necessary?

NCT07399210RecruitingPrimary

Noninvasive Detection of Lung Nodule Malignancy Using cfDNA Fragmentomics

NCT07239063Recruiting

Validation of High-Throughput Large-Format Tissue Preprocessing for Lung and Colorectal Cancer

NCT07393490Not ApplicableRecruitingPrimary

Effect of Apneic Oxygenation of the Non-ventilated Lung During Lung Cancer Surgery.

NCT07384897Not ApplicableRecruitingPrimary

Immune Cells Role in Lung Cancer and Their Use in Anticancer Immunotherapies and Inflammatory Lung Disease

NCT07383454Not ApplicableNot Yet RecruitingPrimary

Lung Cancer Screening in Population Who Had Never Smoked

NCT07363980Enrolling By Invitation

Coronary Computed Tomography Angiography In Rheumatoid Arthritis Study

NCT07370805Not Yet RecruitingPrimary

18F-FAPI PET in Lung Cancer

NCT07354854Not ApplicableCompletedPrimary

Evaluation of the Safety and Effectiveness of the Tri-staple Technology inThoracic Surgery Clinical Investigation

NCT07289646Phase 3Not Yet Recruiting

Functional Lung Avoidance Planning Guided by Lung Perfusion PET/CT Versus Anatomical Planning for Lung Stereotactic Body Radiotherapy

NCT07332156Completed

Lung Cancer Risk in Type 2 Diabetes With COPD: SGLT2 Inhibitors vs. Sulfonylureas

NCT07315672Not ApplicableNot Yet RecruitingPrimary

Acupressure for Cough in Lung Cancer Survivors

Scroll to load more

Research Network

Activity Timeline